210 related articles for article (PubMed ID: 20505768)
1. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival.
Hägglöf C; Hammarsten P; Josefsson A; Stattin P; Paulsson J; Bergh A; Ostman A
PLoS One; 2010 May; 5(5):e10747. PubMed ID: 20505768
[TBL] [Abstract][Full Text] [Related]
2. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting.
Hammarsten P; Dahl Scherdin T; Hägglöf C; Andersson P; Wikström P; Stattin P; Egevad L; Granfors T; Bergh A
PLoS One; 2016; 11(10):e0164016. PubMed ID: 27764093
[TBL] [Abstract][Full Text] [Related]
3. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
[TBL] [Abstract][Full Text] [Related]
4. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
[TBL] [Abstract][Full Text] [Related]
5. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
6. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy.
Wu JP; Huang WB; Zhou H; Xu LW; Zhao JH; Zhu JG; Su JH; Sun HB
Asian J Androl; 2014; 16(5):710-4. PubMed ID: 24875819
[TBL] [Abstract][Full Text] [Related]
7. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
[TBL] [Abstract][Full Text] [Related]
8. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.
Singer E; Linehan J; Babilonia G; Imam SA; Smith D; Loera S; Wilson T; Smith S
PLoS One; 2013; 8(6):e60562. PubMed ID: 23762225
[TBL] [Abstract][Full Text] [Related]
9. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR
Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.
Josefsson A; Adamo H; Hammarsten P; Granfors T; Stattin P; Egevad L; Laurent AE; Wikström P; Bergh A
Am J Pathol; 2011 Oct; 179(4):1961-8. PubMed ID: 21854754
[TBL] [Abstract][Full Text] [Related]
11. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
Nordby Y; Andersen S; Richardsen E; Ness N; Al-Saad S; Melbø-Jørgensen C; Patel HR; Dønnem T; Busund LT; Bremnes RM
Prostate; 2015 Nov; 75(15):1682-93. PubMed ID: 26268996
[TBL] [Abstract][Full Text] [Related]
12. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
13. High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
Kisel W; Conrad S; Borkowetz A; Furesi G; Füssel S; Sommer U; Rauner M; Thomas C; Baretton GB; Schaser KD; Hofbauer C; Hofbauer LC
FEBS Open Bio; 2021 Apr; 11(4):1186-1194. PubMed ID: 33639039
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer.
Rodríguez-Berriguete G; Sánchez-Espiridión B; Cansino JR; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Fraile B; Royuela M
Cytokine; 2013 Nov; 64(2):555-63. PubMed ID: 24063999
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
Henshall SM; Quinn DI; Lee CS; Head DR; Golovsky D; Brenner PC; Delprado W; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2001 Jan; 61(2):423-7. PubMed ID: 11212224
[TBL] [Abstract][Full Text] [Related]
17. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
18. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes.
Webber JP; Spary LK; Mason MD; Tabi Z; Brewis IA; Clayton A
Oncotarget; 2016 Apr; 7(15):20124-39. PubMed ID: 26934553
[TBL] [Abstract][Full Text] [Related]
19. Expression of CAF-Related Proteins Is Associated with Histologic Grade of Breast Phyllodes Tumor.
Kim HM; Lee YK; Koo JS
Dis Markers; 2016; 2016():4218989. PubMed ID: 27881889
[No Abstract] [Full Text] [Related]
20. Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer.
Feferman L; Bhattacharyya S; Deaton R; Gann P; Guzman G; Kajdacsy-Balla A; Tobacman JK
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):277-84. PubMed ID: 23835622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]